These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 9511078

  • 1. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
    Rubinstein E, Bompart F.
    J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
    [Abstract] [Full Text] [Related]

  • 2. Quinupristin-dalfopristin.
    Bryson HM, Spencer CM.
    Drugs; 1996 Sep; 52(3):406-15. PubMed ID: 8875130
    [Abstract] [Full Text] [Related]

  • 3. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.
    Klastersky J.
    Cancer Treat Rev; 2003 Oct; 29(5):431-40. PubMed ID: 12972361
    [Abstract] [Full Text] [Related]

  • 4. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
    Bouanchaud DH.
    J Antimicrob Chemother; 1997 May; 39 Suppl A():15-21. PubMed ID: 9511057
    [Abstract] [Full Text] [Related]

  • 5. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM, Figgitt DP, Faulds D.
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
    Sader HS, Jones RN, Ballow CH, Biedenbach DJ, Cered RF, GSMART Latin America Study Group.
    Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
    [Abstract] [Full Text] [Related]

  • 7. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK.
    Drugs; 2002 Feb; 62(3):425-41. PubMed ID: 11827558
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
    Finch RG.
    Drugs; 1996 Feb; 51 Suppl 1():31-7. PubMed ID: 8724814
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
    Ling TK, Fung KS, Cheng AF.
    Chemotherapy; 2001 Feb; 47(4):243-9. PubMed ID: 11399860
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.
    Speciale A, La Ferla K, Caccamo F, Nicoletti G.
    Int J Antimicrob Agents; 1999 Sep; 13(1):21-8. PubMed ID: 10563401
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.